| 2009-12 |
A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma |
Cancer Chemotherapy and Pharmacology. 2009 Dec;65(1):151-157. |
 |
| 2009-10 |
Pharmacoeconomic analysis of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) in the first line treatment of metastasis colorectal cancer in Taiwan |
Value in Health. 2009 Oct;12(7):A278. |
|
| 2009-09 |
Synergistic augmentation of arsenic trioxide-induced cytotoxicity by BCNU through reactive oxygen species-related autophagic pathway in human solid tumors |
EJC Supplements. 2009 Sep;7(3):16. |
|
| 2009-05-20 |
Differential response of primary or secondary exon 13/14 and exon 17 c-kit mutant to nilotinib and sunitinib: Findings from a cell-based drug-screening platform |
Journal of Clinical Oncology. 2009 May 20;27(15):Abstract number e15636. |
|
| 2009-05-20 |
A phase II study of gemcitabine-based chemoradiotherapy (CCRT) after triplet induction chemotherapy (ICT) for locally advanced pancreatic cancer (LAPC): A Taiwan Cooperative Oncology Group (TCOG) study |
Journal of Clinical Oncology. 2009 May 20;27(15):Abstract number e15562. |
|
| 2009-05-20 |
Helicobacter pylori-independent MALT lymphoma patients responsive to thalidomide-the molecular mechanism and the clinical application |
Journal of Clinical Oncology. 2009 May 20;27(15s):Abstract number e19512. |
|
| 2009-05-20 |
Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC) |
Journal of Clinical Oncology. 2009 May 20;27(15s):Abstract number 4587. |
|
| 2009-05 |
RAD001 (everolimus) suppresses growth of a gastric MALT lymphoma cell Line via downregulation of pAKT/mTOR and BAFF/NF-\#954;B signal transduction pathways |
Cancer Research. 2009 May;69:Abstract number 2762. |
|
| 2009 |
Adjuvant interferon therpay after curative therapy for hepatocellular carcinoma (HCC): A meta-analysis |
Annals of Oncology. 2009;20(Suppl. 7):91. |
|
| 2008-05 |
Cost-minimization analysis of capecitabine for advanced gastric cancer in Taiwan |
Value in Health. 2008 May-Jun;11(3):A64-A65. |
|
| 2008-05 |
Pharmacoeconomic analysis of capecitabine for advanced gastric cancer in Taiwan |
Journal of Clinical Oncology. 2008 May;26(15):Abstract number 15576. |
|
| 2008-05 |
Phase I/II study of capecitabine and PHY906 in hepatocellular carcinoma |
Journal of Clinical Oncology. 2008 May;26(15 Suppl):Abstract number 4610. |
|
| 2008 |
Expression of the nuclear factor kappa B (NFKB) P50/P65 proteins in hepatocellular carcinoma (HCC): Lack of predictive value for response to thalidomide treatment |
Journal of Hepatology. 2008;48(Suppl. 2):S145-S146. |
|
| 2007-09 |
A phase II trial of oxaliplatin with high-dose of 5-fluorouracil and leucovorin in the first-line treatment of inoperable, locally advanced or metastatic biliary tract cancer |
EJC Supplements. 2007 Sep;5(4):268. |
|
| 2007-06 |
H pylori-positive gastric diffuse large B-cell lymphomas are potentially curable by H pylori eradication therapy |
Journal of Clinical Oncology. 2007 Jun;25(18, Suppl.):Meeting Abstract 8093. |
|
| 2007-05 |
Pharmacoeconomic analysis of capecitabine in adjuvant treatment of stage III colon cancer in Taiwan |
Value in Health. 2007 May-Jun;10(3):A11-A12. |
|
| 2006-11 |
Combined modalities of resistance in an oxaliplaitin-resistant human gastric cancer cell line with enhanced sensitivity |
EJC Supplements. 2006 Nov;4(12):59. |
|
| 2005-06 |
An open, multi-center, phase II clinical trial to evaluate efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer preliminary report |
Journal of Clinical Oncology. 2005 Jun;23(16):Abstract number 346S. |
|
| 2004-08-02 |
Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer |
British Journal of Cancer. 2004 Aug;91(3):453-458. |
|
| 2004-08 |
Effect of interleukin-1beta and glutathione S-transferase genotypes on the development of gastric mucosa-associated lymphoid tissue lymphoma |
Haematologica. 2004 Aug;89(8):1015-1017. |
|
| 2004-07 |
Comparison of the antitumor activity of thalidomide between hepatitis B (HBV)and hepatitis C (HCV)-related hepatocellular carcinoma (HCC) |
Journal of Clinical Oncology. 2004 Jul;22(14):Abstract number 362S. |
|
| 2004-06 |
Acute hemorrhagic rectal ulcer syndrome: A new clinical entity? Report of 19 cases and review of the literature |
Diseases of the Colon and Rectum. 2004 Jun;47(6):895-903. |
|
| 2003-11 |
Use of power Doppler sonography and circulating angiogenic factors to assess the potential antiangiogenic effect of thalidomide in hepatocellular carcinoma |
Cancer Epidemiology Biomarkers & Prevention. 2003 Nov;12(11):1288S. |
|
| 2002-11 |
Expression of nuclear BCL10 is highly correlated with the expression of nuclear NF-kB and is predictive of Helicobacter pylori-dependent status in early-stage high-grade gastric MALT lymphoma |
European Journal of Cancer. 2002 Nov;38(Suppl. 7):S162. |
|
| 2002 |
Phase I and pharmacokinetic studies of oral thalidomide in advanced hepatocellular carcinoma |
International Journal of Cancer. 2002;Suppl. 13:336-337. |
|
| 2001-11 |
Use of thalidomide in the treatment of advanced hepatocellular carcinoma (HCC): With emphasis on using power Doppler sonography to evaluate the vascularity of the tumor and its correlation with tumor response |
Clinical Cancer Research. 2001 Nov;7(11):67. |
|
| 1999-09 |
A multi-centre phase II trial of gemcitabine (GEM) and vinorelbine (VRL) in patients (PTS) with stage III-IV non small cell lung cancer (NSCLC) |
European Journal of Cancer. 1999 Sep;35:S259. |
|
| 1999-09 |
Prospective study of anti-H. pylori therapy in stage IE high-grade mucosa-associated lymphoid tissue (hg-MALT) lymphoma of the stomach in Taiwan |
Gut. 1999 Sep;45:A71. |
|
| 1999-09 |
Isolation of a Helicobacter pylori protein, FldA, associated with mucosa-associated lymphoid tissue lymphoma of the stomach |
Gut. 1999 Sep;45:A25. |
|
